Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Jotte · SciRah

Researcher profile · Semantic Scholar

R. Jotte

Share profile

R. Jotte — researcher profile on SciRah

h-index: 34
Works: 151
Citations: 9,177

Most-cited papers

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
M. Socinski, R. Jotte, F. Cappuzzo, F. Orlandi +16 more
2018New England Journal of Medicine3,192 citations Open access
Semantic Scholar
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
M. Reck, T. Mok, M. Nishio, R. Jotte +16 more
2019The Lancet Respiratory Medicine839 citations
Semantic Scholar
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.
R. Jotte, F. Cappuzzo, I. Vynnychenko, D. Stroyakovskiy +14 more
2020Journal of Thoracic Oncology424 citations Open access
Semantic Scholar
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
M. Socinski, M. Nishio, R. Jotte, F. Cappuzzo +15 more
2021Journal of Thoracic Oncology404 citations Open access
Semantic Scholar
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
N. Nogami, F. Barlesi, M. Socinski, M. Reck +19 more
2021Journal of Thoracic Oncology285 citations Open access
Semantic Scholar
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
R. Jotte, F. Cappuzzo, I. Vynnychenko, D. Stroyakovskiy +14 more
2018Journal of Clinical Oncology215 citations
Semantic Scholar
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First‐Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
D. Spigel, C. Reynolds, D. Waterhouse, E. Garon +8 more
2018Journal of Thoracic Oncology214 citations Open access
Semantic Scholar
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
D. Waterhouse, E. Garon, J. Chandler, M. McCleod +19 more
2020Journal of Clinical Oncology205 citations Open access
Semantic Scholar
Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153).
D. Spigel, M. McCleod, R. Jotte, L. Einhorn +17 more
2019Journal of Thoracic Oncology176 citations Open access
Semantic Scholar
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
M. Socinski, R. Jotte, F. Cappuzzo, M. Nishio +8 more
2023JAMA Oncology154 citations Open access
Semantic Scholar
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
H. West, M. Mccleland, F. Cappuzzo, M. Reck +10 more
2022Journal for ImmunoTherapy of Cancer154 citations Open access
Semantic Scholar
Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
M. Socinski, R. Jotte, F. Cappuzzo, F. Orlandi +15 more
201882 citations
Semantic Scholar
1297ORandomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)
D. Spigel, M. McLeod, M. Hussein, D. Waterhouse +16 more
201781 citations Open access
Semantic Scholar
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
T. Mok, Wen-Xiu Yao, M. Duruisseaux, L. Doucet +16 more
2024Journal of Clinical Oncology66 citations Open access
Semantic Scholar
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
F. Barlesi, Wen-Xiu Yao, M. Duruisseaux, L. Doucet +17 more
2025The Lancet64 citations
Semantic Scholar
LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
M. Garassino, W. Theelen, R. Jotte, J. Laskin +14 more
2023Annals of Oncology50 citations
Semantic Scholar
P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153: Topic: IT
D. Spigel, L. Schwartzberg, D. Waterhouse, J. Chandler +11 more
201747 citations Open access
Semantic Scholar
Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).
D. Spigel, R. Jotte, J. Nemunaitis, M. Shum +16 more
2020Journal of Thoracic Oncology45 citations Open access
Semantic Scholar
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
M. Reck, L. Paz-Ares, P. Bidoli, F. Cappuzzo +16 more
2017Lung Cancer44 citations Open access
Semantic Scholar
LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
M. Reck, M. Socinski, F. Cappuzzo, F. Orlandi +15 more
201740 citations Open access
Semantic Scholar
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
K. He, D. Berz, S. Gadgeel, W. Iams +16 more
2023Journal of Thoracic Oncology34 citations Open access
Semantic Scholar
Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups
M. Socinski, T. Mok, M. Nishio, R. Jotte +15 more
2020Tumor Biology33 citations
Semantic Scholar
IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC.
M. Socinski, A. Rittmeyer, D. Shapovalov, F. Orlandi +15 more
2018Annals of Oncology33 citations Open access
Semantic Scholar
OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC
R. Jotte, F. Cappuzzo, I. Vynnychenko, D. Stroyakovskiy +14 more
2019Journal of Thoracic Oncology24 citations Open access
Semantic Scholar
1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations
M. Reck, T. Mok, M. Socinski, R. Jotte +14 more
202023 citations Open access
Semantic Scholar
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).
A. Colevas, C. H. Chung, D. Adkins, Cristina P. Rodriguez +16 more
2024Journal of Clinical Oncology20 citations Open access
Semantic Scholar
Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
M. Socinski, R. Jotte, F. Cappuzzo, M. Nishio +8 more
2021Journal of Clinical Oncology20 citations
Semantic Scholar
1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
T. Leal, D. Berz, I. Rybkin, W. Iams +14 more
2021Annals of Oncology19 citations Open access
Semantic Scholar
1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
H. West, F. Cappuzzo, M. Reck, T. Mok +9 more
202017 citations Open access
Semantic Scholar
IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.
M. Reck, R. Jotte, Tony Mok, D. Lim +14 more
2018Annals of Oncology17 citations Open access
Semantic Scholar
1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
D. Daniel, C. Rudin, L. Hart, D. Spigel +13 more
201717 citations Open access
Semantic Scholar
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
T. Leal, D. Berz, I. Rybkin, W. Iams +14 more
2022Annals of Oncology16 citations Open access
Semantic Scholar
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Tracy Murray-Stewart, D. V. Von Hoff, Michael L. Fitzgerald, L. Marton +11 more
2020Cancer Chemotherapy and Pharmacology16 citations Open access
Semantic Scholar
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
Chao Li, L. Hart, T. Owonikoko, R. Aljumaily +11 more
2021Cancer Chemotherapy and Pharmacology15 citations Open access
Semantic Scholar
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
D. Spigel, R. Jotte, S. Aix, L. Gressot +16 more
2020Clinical Lung Cancer14 citations Open access
Semantic Scholar
Atezolizumab Treatment of Nonsquamous NSCLC.
M. Reck, R. Jotte, M. Socinski
2018New England Journal of Medicine14 citations
Semantic Scholar
IMpower150: Exploratory analysis of brain metastases development.
F. Cappuzzo, M. Reck, M. Socinski, T. Mok +14 more
202012 citations
Semantic Scholar
Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy.
T. Leal, A. Spira, C. Blakely, K. He +12 more
2018Annals of Oncology11 citations Open access
Semantic Scholar
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
Christine H. Chung, A. Colevas, D. Adkins, C. Rodriguez +15 more
2023Journal of Clinical Oncology10 citations
Semantic Scholar
IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)
M. Reck, R. Jotte, F. Cappuzzo, Tony Mok +15 more
2020Pneumologie9 citations
Semantic Scholar
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
C. Langer, Edward S. Kim, E. Anderson, R. Jotte +12 more
2018Frontiers in Oncology9 citations Open access
Semantic Scholar
IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.
T.-S.-K. Mok, M. Socinski, M. Reck, R. Jotte +16 more
2018Annals of Oncology9 citations Open access
Semantic Scholar
LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12
F. Barlesi, W. Yao, M. Duruisseaux, L. Doucet +14 more
2024Annals of Oncology8 citations
Semantic Scholar
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
Michael Thomas, D. Spigel, R. Jotte, M. McCleod +13 more
2017Lung Cancer8 citations Open access
Semantic Scholar
Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
M. Reck, V. Papadimitrakopoulou, F. Cappuzzo, R. Jotte +6 more
20167 citations Open access
Semantic Scholar
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
Sylvia M. Lee, Omid Hamid, R. Jotte, Y. Zakharia +13 more
2024Clinical Cancer Research6 citations Open access
Semantic Scholar
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
M. Evangelist, J. Butrynski, J. Paschold, P. Ward +16 more
2023Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
A. Chiang, C. Rudin, A. Spira, R. Jotte +11 more
20166 citations
Semantic Scholar
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
Tian-Shi Lu, H. Hamidi, Mark A. Socinski, M. Reck +16 more
2025Nature Communications5 citations Open access
Semantic Scholar
IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease.
R. Jotte, M. Batus, E. Bernicker, M. Copur +9 more
20204 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Socinski×24
Invite
M. Socinski — researcher profile on SciRah
M. Reck×18
Invite
M. Reck — researcher profile on SciRah
F. Cappuzzo×15
Invite
F. Cappuzzo — researcher profile on SciRah
D. Rodríguez-Abreu×13
Invite
D. Rodríguez-Abreu — researcher profile on SciRah

×13

Invite

G. Finley — researcher profile on SciRah

Invite

F. Orlandi — researcher profile on SciRah

D. Stroyakovskiy×12

Invite

D. Stroyakovskiy — researcher profile on SciRah

Invite

M. Nishio — researcher profile on SciRah

Invite

N. Nogami — researcher profile on SciRah

Invite

F. Barlesi — researcher profile on SciRah

Anthony Lee×10

Invite

Anthony Lee — researcher profile on SciRah

Invite

G. Shankar — researcher profile on SciRah